Log in

Trevi Therapeutics Stock Price, News & Analysis (NASDAQ:TRVI)

$3.74
-0.04 (-1.06 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$3.53
Now: $3.75
$3.90
50-Day Range
$3.80
MA: $4.55
$5.51
52-Week Range
$3.26
Now: $3.75
$10.62
Volume5,892 shs
Average Volume9,749 shs
Market Capitalization$66.77 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRVI
CUSIPN/A
CIKN/A
Phone203-304-2499

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees15
Market Cap$66.77 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive TRVI News and Ratings via Email

Sign-up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.


Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics Inc (NASDAQ:TRVI) released its earnings results on Monday, August, 12th. The company reported ($0.63) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.22. View Trevi Therapeutics' Earnings History.

When is Trevi Therapeutics' next earnings date?

Trevi Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Trevi Therapeutics.

What price target have analysts set for TRVI?

5 brokers have issued 12 month price targets for Trevi Therapeutics' shares. Their predictions range from $14.00 to $20.00. On average, they expect Trevi Therapeutics' share price to reach $16.75 in the next year. This suggests a possible upside of 347.3% from the stock's current price. View Analyst Price Targets for Trevi Therapeutics.

What is the consensus analysts' recommendation for Trevi Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevi Therapeutics.

Has Trevi Therapeutics been receiving favorable news coverage?

Media headlines about TRVI stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Trevi Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Trevi Therapeutics.

Are investors shorting Trevi Therapeutics?

Trevi Therapeutics saw a decrease in short interest in September. As of September 30th, there was short interest totalling 19,300 shares, a decrease of 8.5% from the August 30th total of 21,100 shares. Based on an average daily volume of 13,500 shares, the short-interest ratio is presently 1.4 days. Currently, 0.7% of the shares of the stock are sold short. View Trevi Therapeutics' Current Options Chain.

Who are some of Trevi Therapeutics' key competitors?

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Canopy Growth (CGC), TransEnterix (TRXC), Bicycle Therapeutics (BCYC), Cara Therapeutics (CARA), Restoration Robotics (HAIR), Kalvista Pharmaceuticals (KALV), AbbVie (ABBV), CannTrust (CTST), Olin (OLN) and Alerian MLP ETF (AMLP).

Who are Trevi Therapeutics' key executives?

Trevi Therapeutics' management team includes the folowing people:
  • Ms. Jennifer L. Good, Co-Founder, CEO, Pres & Director (Age 54)
  • Mr. Thomas R. Sciascia, Co-Founder and Chief Medical Officer (Age 66)
  • Mr. Christopher J. Seiter, Chief Financial Officer (Age 52)
  • Dr. Helena Brett-Smith M.D., Chief Devel. Officer (Age 62)
  • Dr. Amale Hawi, Sr. VP of CMC (Age 65)

When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

When does Trevi Therapeutics' lock-up period expire?

Trevi Therapeutics' lock-up period expires on Monday, November 4th. Trevi Therapeutics had issued 5,500,000 shares in its initial public offering on May 7th. The total size of the offering was $55,000,000 based on an initial share price of $10.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Who are Trevi Therapeutics' major shareholders?

Trevi Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (24.91%). Company insiders that own Trevi Therapeutics stock include Anne Vanlent, Invest A/S Lundbeckfond and Jennifer L Good. View Institutional Ownership Trends for Trevi Therapeutics.

Which institutional investors are buying Trevi Therapeutics stock?

TRVI stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC. Company insiders that have bought Trevi Therapeutics stock in the last two years include Anne Vanlent, Invest A/S Lundbeckfond and Jennifer L Good. View Insider Buying and Selling for Trevi Therapeutics.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $3.75.

How big of a company is Trevi Therapeutics?

Trevi Therapeutics has a market capitalization of $66.77 million. Trevi Therapeutics employs 15 workers across the globe.View Additional Information About Trevi Therapeutics.

What is Trevi Therapeutics' official website?

The official website for Trevi Therapeutics is http://www.trevitherapeutics.com/.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected]


MarketBeat Community Rating for Trevi Therapeutics (NASDAQ TRVI)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  59
MarketBeat's community ratings are surveys of what our community members think about Trevi Therapeutics and other stocks. Vote "Outperform" if you believe TRVI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel